Histologic changes in the breast with menopausal hormone therapy use: Correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices

Menopause

Volumn 15, Issue 1, 2008, Pages 67-73

  Harvey, Jennifer A ^a   Santen, Richard J ^a   Petroni, Gina R ^a   Bovbjerg, Viktor E ^a   Smolkin, Mark E ^a   Sheriff, Fathima S ^b   Russo, Jose ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast; Breast density; Histology; Hormone therapy; Mammography

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIGITAL IMAGING; FEMALE; HISTOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; RETROSPECTIVE STUDY;

BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KI-67 ANTIGEN; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, PROGESTERONE;

EID: 38049055303     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318054e29a     Document Type: Article

References (39)

1. Schairer C, Lubin J, Troist R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
2. Persson IR, Weiderpass E, Bergkvist L, et al. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-260.
3. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
4. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
6. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized control trial. JAMA 2004;291:1701-1712.
7. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-1657.
8. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-1032.
9. Boyd NF, Byng JW, Jong RA. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-675.
10. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-1144.
11. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-1629.
12. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-176.
13. Persson IR, Thurfjell EL, Holmberg LH. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-3207.
14. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-915.
15. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-628.
16. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KP, Kelekis DA, Creatsas GC. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002;9:110-116.
17. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-56.
18. Jackson VP, San Martin JA, Secrest RJ, et al. Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. Am J Obstet Gynecol 2003;188:389-394.
19. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-4565.
20. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;30:262-269.
21. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-37.
22. Purohit A, Ghilchik MW, Leese MP, Potter BV, Reed MJ. Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues. J Steroid Biochem Mol Biol 2005;94:167-172.
23. Reed MJ, Purohit A. Aromatase regulation and breast cancer. Clin Endocrinol 2001;54:563-571.
24. Singh A, Purohit A, Duncan LJ, Mokbel K, Ghilchik MW, Reed MJ. Control of aromatase activity in breast tumours: the role of the immune system. J Steroid Biochem Mol Biol 1997;61:185-192.
25. Anderson E, Clarke RB, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 1998;3:23-35.
26. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004;230:29-41.
27. Vacek PM, Geller BM. A prospective study of breast cancer risk using routine mammographic breast density measurements. Cancer Epidemiol Biomarkers Prev 2004;13:715-722.
28. Nagata C, Matsubara T, Fujita H, et al. Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer 2005;92:2102-2106.
29. Page DL, Winfield AC. The dense mammogram. AJR Am J Roentgenol 1986;147:487-489.
30. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865-874.
31. Byng JW, Yaffe MJ, Jong RA, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 1998;18:1587-1598.
32. Russo J, Russo IH. Development of human mammary gland. In: Neville MC, Daniel CW, eds. The Mammary Gland: Development, Regulation, and Function. New York, NY: Plenum Publishing Corp, 1987:67-93.
33. Palmieri C, Saji S, Sakaguchi H, et al. The expression of oestrogen receptor (ER)-β and its variants, but not ERα, in adult human mammary fibroblasts. J Mol Endocrinol 2004;33:35-50.
34. Parmar H, Cunha GR. Epithelial-stromal interactions in the mouse and human mammary gland in vivo. Endocr Relat Cancer 2004;11:437-458.
35. Garmy-Susini B, Delmas E, Gourdy P, et al. Role of fibroblast growth factor-2 isoforms in the effect of estradiol on endothelial cell migration and proliferation. Circ Res 2004;94:1301-1309.
36. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumori-genesis. Lab Invest 1990;62:244-278.
37. Russo J, Russo IH. Biological and Molecular Basis of Breast Cancer. Heidelberg, Germany: Springer-Verlag, 2004.
38. Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999;53:217-227.
39. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000;60:3744-3748.